Видео ютуба по тегу Lbcl

The current role of SCT in LBCL in the era of novel therapies: identifying patients who may benefit
The current role of SCT in LBCL in the era of novel therapies: identifying patients who may benefit
Using LBCL LymphoMAPs to identify subgroups of patients who benefit from CAR T-cell therapy
Using LBCL LymphoMAPs to identify subgroups of patients who benefit from CAR T-cell therapy
Unmet needs in LBCL: treatment options for elderly or frail patients
Unmet needs in LBCL: treatment options for elderly or frail patients
How to Treat Diffuse Large B-Cell Lymphoma (DLBCL) in 2025
How to Treat Diffuse Large B-Cell Lymphoma (DLBCL) in 2025
R/R Large B-cell Lymphoma (LBCL): after ASH 2024
R/R Large B-cell Lymphoma (LBCL): after ASH 2024
Biologic Synergy in Focus: Liso-cel and NKTR-255 in Advanced LBCL
Biologic Synergy in Focus: Liso-cel and NKTR-255 in Advanced LBCL
The role of alloSCT for R/R LBCL in the era of CAR-T therapy
The role of alloSCT for R/R LBCL in the era of CAR-T therapy
Management and outcomes of elderly patients with LBCL
Management and outcomes of elderly patients with LBCL
Current and emerging indications for CAR-T therapy in LBCL
Current and emerging indications for CAR-T therapy in LBCL
Advantages of bispecific antibodies over CAR-T therapy in LBCL
Advantages of bispecific antibodies over CAR-T therapy in LBCL
Axi-cel in patients with R/R LBCL in complete metabolic response
Axi-cel in patients with R/R LBCL in complete metabolic response
CD19 Targeted CAR T-cell Therapy in LBCL
CD19 Targeted CAR T-cell Therapy in LBCL
Long-term follow-up with bispecific antibodies in follicular lymphoma and LBCL
Long-term follow-up with bispecific antibodies in follicular lymphoma and LBCL
Optimizing CAR-T therapy in LBCL
Optimizing CAR-T therapy in LBCL
Impact of age on toxicity & outcomes in patients with LBCL treated with CD19-directed CAR-T therapy
Impact of age on toxicity & outcomes in patients with LBCL treated with CD19-directed CAR-T therapy
Phase II study of glofitamab in patients with R/R LBCL
Phase II study of glofitamab in patients with R/R LBCL
Updates in the treatment of R/R LBCL: promising novel agents in the pipeline
Updates in the treatment of R/R LBCL: promising novel agents in the pipeline
The role of CAR-T therapy in high-risk LBCL in the first and second-line settings
The role of CAR-T therapy in high-risk LBCL in the first and second-line settings
CAR T-cell durability in LBCL: antigen presentation, immune engagement, and HLA loss
CAR T-cell durability in LBCL: antigen presentation, immune engagement, and HLA loss
Phase Ib study of JNJ-4496 in R/R LBCL: early safety & efficacy data
Phase Ib study of JNJ-4496 in R/R LBCL: early safety & efficacy data
Inferior outcomes of European vs. US patients with R/R LBCL after CD19 CAR-T cell therapy
Inferior outcomes of European vs. US patients with R/R LBCL after CD19 CAR-T cell therapy
Treatment options for patients with LBCL who relapse or are refractory to initial treatment
Treatment options for patients with LBCL who relapse or are refractory to initial treatment
Treatment Outcomes for LBCL with Central Nervous System Involvement | Juan Alderuccio, MD | #ASH24
Treatment Outcomes for LBCL with Central Nervous System Involvement | Juan Alderuccio, MD | #ASH24
Frederick Locke: Axi-Cel Vs. Standard of Care in Aggressive LBCL
Frederick Locke: Axi-Cel Vs. Standard of Care in Aggressive LBCL
Long-term outcome of patients with R/R LBCL achieving CR using bispecific antibodies
Long-term outcome of patients with R/R LBCL achieving CR using bispecific antibodies